Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · March 10, 2023

Long-Term Outcomes After Rituximab Treatment in Patients With Systemic Sclerosis

JAMA Dermatology


Additional Info

JAMA Dermatology
Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels
JAMA Dermatol 2023 Feb 15;[EPub Ahead of Print], A Kuzumi, S Ebata, T Fukasawa, KM Matsuda, H Kotani, A Yoshizaki-Ogawa, S Sato, A Yoshizaki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading